Talphera (TLPH) Jumps 36.61% After $5 Million CorMedix Investment—Phase 3 Study in Focus
Stock Soars as CorMedix Takes $5 Million Stake at $0.55 Per Share
Talphera’s (NASDAQ:TLPH) shares surged 36.61% in morning trading, reaching $0.75 at 10:58 AM after CorMedix Inc. (NASDAQ:CRMD) revealed a $5 million minority investment. The transaction saw CorMedix acquire 9,090,909 shares in a private placement at an at-market price of $0.55 per share, a move aimed at advancing Talphera’s lead candidate, Niyad™.
Proceeds Power Ongoing Phase 3 Niyad™ Study for Critical Kidney Patients
The capital infusion is set to fund the completion of Talphera’s ongoing Phase 3 NEPHRO CRRT study for Niyad™. This FDA Breakthrough Device is a potential first-in-class anticoagulant for patients undergoing continuous renal replacement therapy (CRRT), particularly those unable to tolerate heparin or at increased bleeding risk. The randomized, double-blind trial targets enrollment of 70 adult CRRT patients—a critical patient group, as an estimated 165,000 U.S. acute kidney injury patients receive 5–7 days of CRRT each year in hospital ICUs.
Deal Structure Grants CorMedix Acquisition Negotiation Rights
Beyond equity, the agreement also grants CorMedix the exclusive right of first negotiation for a potential Talphera acquisition, starting with a 60-day exclusivity window following Phase 3 results. CorMedix can also nominate a director to Talphera’s board—tightening their strategic alignment.
| Key Metric | Value |
|---|---|
| Stock Price (10:58 AM) | $0.75 |
| Change ($) | +0.20 |
| Change (%) | +36.61% |
| CorMedix Investment | $5 million |
| Shares Acquired | 9,090,909 |
| Purchase Price per Share | $0.55 |
| Target Phase 3 Enrollment | 70 patients |
Potential for a New Standard of Care in Acute Renal Therapy
If successful, Niyad™ would become the first FDA-approved regional anticoagulant for CRRT, aiming to fill an important gap in ICU kidney care. Both Talphera’s CEO and CorMedix leadership highlighted the strategic value and market need—CorMedix describing the move as part of its strategy to invest in undervalued and synergistic assets. The anticipated study completion is set for the end of 2025, with possible regulatory submission in 2026.
Takeaway: Clinical Results and Acquisition Talks Will Drive the Next Chapter
With CorMedix’s capital and a seat at the negotiation table, all eyes are now on the NEPHRO CRRT study’s progress and future FDA decisions. For investors, Talphera’s near-term milestones—including Phase 3 completion and possible acquisition overtures—may be the next major catalysts to watch.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.